Monoclonal antibody therapy directed against certain pathways leading to the eventual cellular immune reaction to an irritating agent has been a mainstay of therapy for many pathological conditions considered autoimmune in nature. Unfortunately, these monoclonal antibody therapies are extremely expensive, and may lead to some serious adverse complication e.g., risk of infection or developing cancer based on generalized immune suppression, and other less common adverse effects that may be quickly lethal. Some of these autoimmune conditions may over time show a greater frequency of other types of autoimmune pathology. For example, patients with rheumatoid arthritis and inflammatory bowel disease may develop subsequently certain autoimmune skin disorders e.g., pyoderma gangrenosum. Interestingly dopamine agonists have been found to very effectively ameliorate rheumatoid arthritis, inflammatory bowel disease, and many autoimmune skin disorders that previously failed to respond adequately to these other biological immunosuppressants A case of a 51-year-old woman with a long history of rheumatoid arthritis had failed to respond adequately to immune suppression with high dosage, glucocorticoids and could not tolerate either Etanercept or Adalimumab. However, for many years, her joint pain and fatigue were markedly improved following treatment with the dopamine agonist dextroamphetamine sulfate. After many years on dextroamphetamine, she developed pyoderma gangrenosum, which not only failed to improve despite two courses of infliximab, unfortunately she had a very severe reaction to the drug. She did have marked improvement, however, with the addition of another dopamine agonist carbidopa levodopa. The hypothesized mechanism of action of dopamine agonists is to correct tissue permeability defects, thus inhibiting irritating agents from crossing the mucosal barrier leading to severe inflammation.